Emerging MRI-Based Technology for Assessing Muscle and Fat Gets FDA 510(k) Clearance
Utilizing biomarkers from magnetic resonance imaging (MRI) exams, AMRA Medical’s BCP Scan reportedly provides precise measurements of muscle and fat.
The Food and Drug Administration (FDA) has granted 510(k) clearance to the BCP (Body Composition Profile) Scan, a technology that enables clinicians to obtain accurate muscle and fat measurements from magnetic resonance imaging (MRI), according to AMRA Medical.
In contrast to obtaining a body mass index (BMI) or waist circumference number, AMRA Medical said its BCP Scan offers specific measurements of muscle, fat, and liver fat volumes. The company noted these measurements may help clinicians educate patients on associated health risks and initiate conversations about lifestyle changes to mitigate these risks.
For example, the BCP Scan can reportedly identify people with high visceral fat and low liver fat, a combination associated with a high heart disease risk, according to AMRA Medical. The company also suggested that the BCP Scan can help monitor weight loss efforts for obese people by determining whether they are losing visceral fat or if they are only losing subcutaneous fat.
AMRA Medical says its protocol for the BCP Scan only adds a couple of minutes to a prescribed MRI exam and generates a report that compares the patient’s body composition measurements to normative values from the company’s reference database as well as others of the same sex and body habitus.
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
Could Ultrafast MRI Enhance Detection of Malignant Foci for Breast Cancer?
April 10th 2025In a new study involving over 120 women, nearly two-thirds of whom had a family history of breast cancer, ultrafast MRI findings revealed a 5 percent increase in malignancy risk for each second increase in the difference between lesion and background parenchymal enhancement (BPE) time to enhancement (TTE).
